메뉴 건너뛰기




Volumn 1, Issue 17, 2016, Pages

The head and neck cancer immune landscape and its immunotherapeutic implications

Author keywords

[No Author keywords available]

Indexed keywords


EID: 85055611916     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.89829     Document Type: Article
Times cited : (591)

References (81)
  • 1
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid O, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144.
    • (2013) N Engl J Med , vol.369 , Issue.2 , pp. 134-144
    • Hamid, O1
  • 2
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
    • (2010) N Engl J Med , vol.363 , Issue.8 , pp. 711-723
    • Hodi, FS1
  • 3
    • 84920956735 scopus 로고    scopus 로고
    • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    • Herbst RS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
    • (2014) Nature , vol.515 , Issue.7528 , pp. 563-567
    • Herbst, RS1
  • 4
    • 84920956732 scopus 로고    scopus 로고
    • PD-1 blockade induces responses by inhibiting adaptive immune resistance
    • Tumeh PC, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
    • (2014) Nature , vol.515 , Issue.7528 , pp. 568-571
    • Tumeh, PC1
  • 5
    • 84905083767 scopus 로고    scopus 로고
    • PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
    • Tykodi SS. PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. Onco Targets Ther. 2014;7:1349–1359.
    • (2014) Onco Targets Ther , vol.7 , pp. 1349-1359
    • Tykodi, SS.1
  • 7
    • 51649093834 scopus 로고    scopus 로고
    • Recent advances in head and neck cancer
    • Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143–1154.
    • (2008) N Engl J Med , vol.359 , Issue.11 , pp. 1143-1154
    • Haddad, RI1    Shin, DM.2
  • 9
    • 80051580618 scopus 로고    scopus 로고
    • Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths
    • Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212–236.
    • (2011) CA Cancer J Clin , vol.61 , Issue.4 , pp. 212-236
    • Siegel, R1    Ward, E2    Brawley, O3    Jemal, A.4
  • 10
    • 84925296349 scopus 로고    scopus 로고
    • Therapeutic insights from genomic studies of head and neck squamous cell carcinomas
    • Hammerman PS, Hayes DN, Grandis JR. Therapeutic insights from genomic studies of head and neck squamous cell carcinomas. Cancer Discov. 2015;5(3):239–244.
    • (2015) Cancer Discov , vol.5 , Issue.3 , pp. 239-244
    • Hammerman, PS1    Hayes, DN2    Grandis, JR.3
  • 11
    • 34250180582 scopus 로고    scopus 로고
    • Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
    • Vermorken JB, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171–2177.
    • (2007) J Clin Oncol , vol.25 , Issue.16 , pp. 2171-2177
    • Vermorken, JB1
  • 12
    • 84923197605 scopus 로고    scopus 로고
    • Comprehensive genomic characterization of head and neck squamous cell carcinomas
    • Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576–582.
    • (2015) Nature , vol.517 , Issue.7536 , pp. 576-582
  • 13
    • 84961289657 scopus 로고    scopus 로고
    • Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas
    • Seiwert TY, et al. Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin Cancer Res. 2015;21(3):632–641.
    • (2015) Clin Cancer Res , vol.21 , Issue.3 , pp. 632-641
    • Seiwert, TY1
  • 14
    • 80052177544 scopus 로고    scopus 로고
    • Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1
    • Agrawal N, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 2011;333(6046):1154–1157.
    • (2011) Science , vol.333 , Issue.6046 , pp. 1154-1157
    • Agrawal, N1
  • 15
    • 80052158097 scopus 로고    scopus 로고
    • The mutational landscape of head and neck squamous cell carcinoma
    • Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157–1160.
    • (2011) Science , vol.333 , Issue.6046 , pp. 1157-1160
    • Stransky, N1
  • 16
    • 84989299727 scopus 로고    scopus 로고
    • Efficacy safety of pembrolizumab in recurrent/metastatic head neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012 [abstract 6012]
    • Mehra R,et al. Efficacy safety of pembrolizumab in recurrent/metastatic head neck squamous cell carcinoma (R/M HNSCC): Pooled analyses after long-term follow-up in KEYNOTE-012 [abstract 6012]. J Clin Oncol. 2016;34.
    • (2016) J Clin Oncol , vol.34
    • Mehra, R1
  • 17
    • 85010325337 scopus 로고    scopus 로고
    • Nivolumab (nivo) vs investigator’s choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141
    • Paper presented at: April 19, New Orleans, LA
    • Gillison ML, et al. Nivolumab (nivo) vs investigator’s choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141. Paper presented at: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; April 19, 2016; New Orleans, LA.
    • (2016) Proceedings of the 107th Annual Meeting of the American Association for Cancer Research
    • Gillison, ML1
  • 18
    • 84989351990 scopus 로고    scopus 로고
    • Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head neck (SCCHN): CheckMate 141 [abstract 6009]
    • Ferris RL, et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head neck (SCCHN): CheckMate 141 [abstract 6009]. J Clin Oncol. 2016;34.
    • (2016) J Clin Oncol , vol.34
    • Ferris, RL1
  • 20
    • 84920962202 scopus 로고    scopus 로고
    • Molecular and genetic properties of tumors associated with local immune cytolytic activity
    • Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160(1-2):48–61.
    • (2015) Cell , vol.160 , Issue.1-2 , pp. 48-61
    • Rooney, MS1    Shukla, SA2    Wu, CJ3    Getz, G4    Hacohen, N.5
  • 21
    • 2342492313 scopus 로고    scopus 로고
    • Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
    • Chung CH, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5(5):489–500.
    • (2004) Cancer Cell , vol.5 , Issue.5 , pp. 489-500
    • Chung, CH1
  • 22
    • 84874327940 scopus 로고    scopus 로고
    • Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes
    • Walter V, et al. Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes. PLoS One. 2013;8(2):e56823.
    • (2013) PLoS One , vol.8 , Issue.2 , pp. e56823
    • Walter, V1
  • 23
    • 84882837534 scopus 로고    scopus 로고
    • Signatures of mutational processes in human cancer
    • Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
    • (2013) Nature , vol.500 , Issue.7463 , pp. 415-421
    • Alexandrov, LB1
  • 24
    • 67349186983 scopus 로고    scopus 로고
    • How cigarette smoke skews immune responses to promote infection, lung disease and cancer
    • Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. Nat Rev Immunol. 2009;9(5):377–384.
    • (2009) Nat Rev Immunol , vol.9 , Issue.5 , pp. 377-384
    • Stämpfli, MR1    Anderson, GP.2
  • 25
    • 84928761118 scopus 로고    scopus 로고
    • Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
    • Rizvi NA, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
    • (2015) Science , vol.348 , Issue.6230 , pp. 124-128
    • Rizvi, NA1
  • 26
    • 84918828514 scopus 로고    scopus 로고
    • Genetic basis for clinical response to CTLA-4 blockade in melanoma
    • Snyder A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
    • (2014) N Engl J Med , vol.371 , Issue.23 , pp. 2189-2199
    • Snyder, A1
  • 27
    • 84932628341 scopus 로고    scopus 로고
    • PD-1 blockade in tumors with mismatch-repair deficiency
    • Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
    • (2015) N Engl J Med , vol.372 , Issue.26 , pp. 2509-2520
    • Le, DT1
  • 28
    • 85020869806 scopus 로고    scopus 로고
    • Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012
    • Chow L, et al. Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012. Eur J Cancer. 2015;51(3):S579. doi: 10.1016/S0959-8049(16)31604-5.
    • (2015) Eur J Cancer , vol.51 , Issue.3 , pp. S579
    • Chow, L1
  • 29
    • 85136205070 scopus 로고    scopus 로고
    • Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort [abstract LBA6008]
    • Seiwert TY, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort [abstract LBA6008]. J Clin Oncol. 2015;33.
    • (2015) J Clin Oncol , vol.33
    • Seiwert, TY1
  • 31
    • 78650970845 scopus 로고    scopus 로고
    • Innate or adaptive immunity? The example of natural killer cells
    • Vivier E, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011;331(6013):44–49.
    • (2011) Science , vol.331 , Issue.6013 , pp. 44-49
    • Vivier, E1
  • 32
    • 84951310757 scopus 로고    scopus 로고
    • NK cells and cancer: you can teach innate cells new tricks
    • Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer. 2016;16(1):7–19.
    • (2016) Nat Rev Cancer , vol.16 , Issue.1 , pp. 7-19
    • Morvan, MG1    Lanier, LL.2
  • 33
    • 84869856060 scopus 로고    scopus 로고
    • A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
    • Vey N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120(22):4317–4323.
    • (2012) Blood , vol.120 , Issue.22 , pp. 4317-4323
    • Vey, N1
  • 34
    • 84942933304 scopus 로고    scopus 로고
    • A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma
    • Benson DM, et al. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2015;21(18):4055–4061.
    • (2015) Clin Cancer Res , vol.21 , Issue.18 , pp. 4055-4061
    • Benson, DM1
  • 35
    • 61449115971 scopus 로고    scopus 로고
    • CD56bright natural killer (NK) cells: an important NK cell subset
    • Poli A, Michel T, Thérésine M, Andrès E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465.
    • (2009) Immunology , vol.126 , Issue.4 , pp. 458-465
    • Poli, A1    Michel, T2    Thérésine, M3    Andrès, E4    Hentges, F5    Zimmer, J.6
  • 36
    • 77954190940 scopus 로고    scopus 로고
    • Human papillomavirus and survival of patients with oropharyngeal cancer
    • Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.
    • (2010) N Engl J Med , vol.363 , Issue.1 , pp. 24-35
    • Ang, KK1
  • 37
    • 84858800620 scopus 로고    scopus 로고
    • The immune contexture in human tumours: impact on clinical outcome
    • Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298–306.
    • (2012) Nat Rev Cancer , vol.12 , Issue.4 , pp. 298-306
    • Fridman, WH1    Pagès, F2    Sautès-Fridman, C3    Galon, J.4
  • 38
    • 36849010167 scopus 로고    scopus 로고
    • Adaptive immunity maintains occult cancer in an equilibrium state
    • Koebel CM, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450(7171):903–907.
    • (2007) Nature , vol.450 , Issue.7171 , pp. 903-907
    • Koebel, CM1
  • 39
    • 0035953308 scopus 로고    scopus 로고
    • IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity
    • Shankaran V, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410(6832):1107–1111.
    • (2001) Nature , vol.410 , Issue.6832 , pp. 1107-1111
    • Shankaran, V1
  • 40
    • 33749319703 scopus 로고    scopus 로고
    • Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
    • Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
    • (2006) Science , vol.313 , Issue.5795 , pp. 1960-1964
    • Galon, J1
  • 41
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: the next generation
    • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
    • (2011) Cell , vol.144 , Issue.5 , pp. 646-674
    • Hanahan, D1    Weinberg, RA.2
  • 42
    • 47949096781 scopus 로고    scopus 로고
    • Cancer-related inflammation
    • Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444.
    • (2008) Nature , vol.454 , Issue.7203 , pp. 436-444
    • Mantovani, A1    Allavena, P2    Sica, A3    Balkwill, F.4
  • 43
    • 84938984463 scopus 로고    scopus 로고
    • The prognostic landscape of genes and infiltrating immune cells across human cancers
    • Gentles AJ, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
    • (2015) Nat Med , vol.21 , Issue.8 , pp. 938-945
    • Gentles, AJ1
  • 44
    • 84866754237 scopus 로고    scopus 로고
    • An immunosurveillance mechanism controls cancer cell ploidy
    • Senovilla L, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012;337(6102):1678–1684.
    • (2012) Science , vol.337 , Issue.6102 , pp. 1678-1684
    • Senovilla, L1
  • 45
    • 78049248432 scopus 로고    scopus 로고
    • Allele-specific copy number analysis of tumors
    • Van Loo P, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA. 2010;107(39):16910–16915.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.39 , pp. 16910-16915
    • Van Loo, P1
  • 46
    • 84885673911 scopus 로고    scopus 로고
    • Inferring tumour purity and stromal and immune cell admixture from expression data
    • Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
    • (2013) Nat Commun , vol.4 , pp. 2612
    • Yoshihara, K1
  • 47
    • 84922394461 scopus 로고    scopus 로고
    • Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss
    • Gross AM, et al. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat Genet. 2014;46(9):939–943.
    • (2014) Nat Genet , vol.46 , Issue.9 , pp. 939-943
    • Gross, AM1
  • 48
    • 43749112760 scopus 로고    scopus 로고
    • Vascular normalization in Rgs5-deficient tumours promotes immune destruction
    • Hamzah J, et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature. 2008;453(7193):410–414.
    • (2008) Nature , vol.453 , Issue.7193 , pp. 410-414
    • Hamzah, J1
  • 49
    • 84901290212 scopus 로고    scopus 로고
    • Releasing pressure in tumors: what do we know so far and where do we go from here? A review
    • Ariffin AB, Forde PF, Jahangeer S, Soden DM, Hinchion J. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res. 2014;74(10):2655–2662.
    • (2014) Cancer Res , vol.74 , Issue.10 , pp. 2655-2662
    • Ariffin, AB1    Forde, PF2    Jahangeer, S3    Soden, DM4    Hinchion, J.5
  • 50
    • 33748987908 scopus 로고    scopus 로고
    • Cancer despite immunosurveillance: immunoselection and immunosubversion
    • Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6(10):715–727.
    • (2006) Nat Rev Immunol , vol.6 , Issue.10 , pp. 715-727
    • Zitvogel, L1    Tesniere, A2    Kroemer, G.3
  • 51
    • 2442585121 scopus 로고    scopus 로고
    • Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
    • Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4(5):336–347.
    • (2004) Nat Rev Immunol , vol.4 , Issue.5 , pp. 336-347
    • Chen, L.1
  • 52
    • 44349150012 scopus 로고    scopus 로고
    • Inhibitory B7-family molecules in the tumour microenvironment
    • Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477.
    • (2008) Nat Rev Immunol , vol.8 , Issue.6 , pp. 467-477
    • Zou, W1    Chen, L.2
  • 53
    • 18544380239 scopus 로고    scopus 로고
    • Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion
    • Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800.
    • (2002) Nat Med , vol.8 , Issue.8 , pp. 793-800
    • Dong, H1
  • 54
    • 34447646310 scopus 로고    scopus 로고
    • Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
    • Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122.
    • (2007) Immunity , vol.27 , Issue.1 , pp. 111-122
    • Butte, MJ1    Keir, ME2    Phamduy, TB3    Sharpe, AH4    Freeman, GJ.5
  • 55
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717–1725.
    • (2009) J Exp Med , vol.206 , Issue.8 , pp. 1717-1725
    • Peggs, KS1    Quezada, SA2    Chambers, CA3    Korman, AJ4    Allison, JP.5
  • 56
    • 84878936788 scopus 로고    scopus 로고
    • Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells
    • Selby MJ, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1(1):32–42.
    • (2013) Cancer Immunol Res , vol.1 , Issue.1 , pp. 32-42
    • Selby, MJ1
  • 57
    • 84884271914 scopus 로고    scopus 로고
    • Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
    • Simpson TR, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013;210(9):1695–1710.
    • (2013) J Exp Med , vol.210 , Issue.9 , pp. 1695-1710
    • Simpson, TR1
  • 58
    • 84942138310 scopus 로고    scopus 로고
    • Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D [abstract 8011]
    • Patnaik A, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D [abstract 8011]. J Clin Oncol. 2015;33.
    • (2015) J Clin Oncol , vol.33
    • Patnaik, A1
  • 59
    • 79957936035 scopus 로고    scopus 로고
    • Indoleamine 2,3-dioxygenase, Tregs and cancer
    • Munn DH. Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem. 2011;18(15):2240–2246.
    • (2011) Curr Med Chem , vol.18 , Issue.15 , pp. 2240-2246
    • Munn, DH.1
  • 60
    • 84897933432 scopus 로고    scopus 로고
    • GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability
    • Schaer DA, et al. GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res. 2013;1(5):320–331.
    • (2013) Cancer Immunol Res , vol.1 , Issue.5 , pp. 320-331
    • Schaer, DA1
  • 61
    • 84874996294 scopus 로고    scopus 로고
    • ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection
    • Redpath SA, et al. ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection. Eur J Immunol. 2013;43(3):705–715.
    • (2013) Eur J Immunol , vol.43 , Issue.3 , pp. 705-715
    • Redpath, SA1
  • 62
    • 84977564001 scopus 로고    scopus 로고
    • Personalized oncology meets immunology: the path toward precision immunotherapy
    • Mandal R, Chan TA. Personalized oncology meets immunology: the path toward precision immunotherapy. Cancer Discov. 2016;6(7):703–713.
    • (2016) Cancer Discov , vol.6 , Issue.7 , pp. 703-713
    • Mandal, R1    Chan, TA.2
  • 63
    • 78149281950 scopus 로고    scopus 로고
    • A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients
    • Adotevi O, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother. 2010;33(9):991–998.
    • (2010) J Immunother , vol.33 , Issue.9 , pp. 991-998
    • Adotevi, O1
  • 64
    • 0034715948 scopus 로고    scopus 로고
    • Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population
    • Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356(9244):1795–1799.
    • (2000) Lancet , vol.356 , Issue.9244 , pp. 1795-1799
    • Imai, K1    Matsuyama, S2    Miyake, S3    Suga, K4    Nakachi, K.5
  • 65
    • 0022476775 scopus 로고
    • Natural killer cell activity and head and neck cancer: a clinical assessment
    • Schantz SP, Shillitoe EJ, Brown B, Campbell B. Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst. 1986;77(4):869–875.
    • (1986) J Natl Cancer Inst , vol.77 , Issue.4 , pp. 869-875
    • Schantz, SP1    Shillitoe, EJ2    Brown, B3    Campbell, B.4
  • 66
    • 0027368830 scopus 로고
    • Role of natural killer cells in cancer
    • Pross HF, Lotzová E. Role of natural killer cells in cancer. Nat Immun. 1993;12(4-5):279–292.
    • (1993) Nat Immun , vol.12 , Issue.4-5 , pp. 279-292
    • Pross, HF1    Lotzová, E.2
  • 67
    • 0019193024 scopus 로고
    • Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice
    • Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J Natl Cancer Inst. 1980;65(5):929–935.
    • (1980) J Natl Cancer Inst , vol.65 , Issue.5 , pp. 929-935
    • Talmadge, JE1    Meyers, KM2    Prieur, DJ3    Starkey, JR.4
  • 68
    • 84875509728 scopus 로고    scopus 로고
    • Regulation of ligands for the NKG2D activating receptor
    • Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor. Annu Rev Immunol. 2013;31:413–441.
    • (2013) Annu Rev Immunol , vol.31 , pp. 413-441
    • Raulet, DH1    Gasser, S2    Gowen, BG3    Deng, W4    Jung, H.5
  • 69
    • 84899004889 scopus 로고    scopus 로고
    • Natural cytotoxicity receptors and their ligands
    • Kruse PH, Matta J, Ugolini S, Vivier E. Natural cytotoxicity receptors and their ligands. Immunol Cell Biol. 2014;92(3):221–229.
    • (2014) Immunol Cell Biol , vol.92 , Issue.3 , pp. 221-229
    • Kruse, PH1    Matta, J2    Ugolini, S3    Vivier, E.4
  • 70
    • 84902137525 scopus 로고    scopus 로고
    • Targeting CD137 enhances the efficacy of cetuximab
    • Kohrt HE, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest. 2014;124(6):2668–2682.
    • (2014) J Clin Invest , vol.124 , Issue.6 , pp. 2668-2682
    • Kohrt, HE1
  • 71
    • 84925743331 scopus 로고    scopus 로고
    • Balancing natural killer cell activation through paired receptors
    • Martinet L, Smyth MJ. Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 2015;15(4):243–254.
    • (2015) Nat Rev Immunol , vol.15 , Issue.4 , pp. 243-254
    • Martinet, L1    Smyth, MJ.2
  • 72
    • 84864999052 scopus 로고    scopus 로고
    • PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection
    • Norris S, Coleman A, Kuri-Cervantes L, Bower M, Nelson M, Goodier MR. PD-1 expression on natural killer cells and CD8(+) T cells during chronic HIV-1 infection. Viral Immunol. 2012;25(4):329–332.
    • (2012) Viral Immunol , vol.25 , Issue.4 , pp. 329-332
    • Norris, S1    Coleman, A2    Kuri-Cervantes, L3    Bower, M4    Nelson, M5    Goodier, MR.6
  • 73
    • 77957701558 scopus 로고    scopus 로고
    • The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
    • Benson DM, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–2294.
    • (2010) Blood , vol.116 , Issue.13 , pp. 2286-2294
    • Benson, DM1
  • 74
    • 84958555198 scopus 로고    scopus 로고
    • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
    • Koyama S, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501.
    • (2016) Nat Commun , vol.7 , pp. 10501
    • Koyama, S1
  • 75
    • 78049243425 scopus 로고    scopus 로고
    • Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth
    • Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res. 2010;70(20):7800–7809.
    • (2010) Cancer Res , vol.70 , Issue.20 , pp. 7800-7809
    • Teng, MW1    Ngiow, SF2    von Scheidt, B3    McLaughlin, N4    Sparwasser, T5    Smyth, MJ.6
  • 76
    • 84928199174 scopus 로고    scopus 로고
    • STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
    • Fu J, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52.
    • (2015) Sci Transl Med , vol.7 , Issue.283 , pp. 283ra52
    • Fu, J1
  • 77
    • 84885137302 scopus 로고    scopus 로고
    • Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser
    • Cline MS, et al. Exploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser. Sci Rep. 2013;3:2652.
    • (2013) Sci Rep , vol.3 , pp. 2652
    • Cline, MS1
  • 78
    • 84885724091 scopus 로고    scopus 로고
    • Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer
    • Bindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795.
    • (2013) Immunity , vol.39 , Issue.4 , pp. 782-795
    • Bindea, G1
  • 79
    • 70449091786 scopus 로고    scopus 로고
    • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    • Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112.
    • (2009) Nature , vol.462 , Issue.7269 , pp. 108-112
    • Barbie, DA1
  • 80
    • 84928927858 scopus 로고    scopus 로고
    • Robust enumeration of cell subsets from tissue expression profiles
    • Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457.
    • (2015) Nat Methods , vol.12 , Issue.5 , pp. 453-457
    • Newman, AM1
  • 81
    • 84891102589 scopus 로고    scopus 로고
    • Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
    • Alexandrov LB, Stratton MR. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev. 2014;24:52–60.
    • (2014) Curr Opin Genet Dev , vol.24 , pp. 52-60
    • Alexandrov, LB1    Stratton, MR.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.